INTRODUCTION

The methylenetetrahydrofolate reductase gene mutation, known as MTHFR is a relatively new discovery. Approximately 35% of the U.S. population have a form of the MTHFR gene mutation (Rady et al, 1999).

Table 1 MTHFR MUTATION FREQUENCY

Population	Allele frequency	References
Colombian	0.487	Camacho-Vanegas et al., 1998
Northern Italy	0.45	Sacchi et al., 1997
South Europe	0.41	Gudnason et al., 1998
Italian	0.40	de Franchis et al., 1996
Asian	0.4	Franco et al., 1998
French-Canadian	0.38	Frosst et al., 1995
Australian	0.37	Wilcken et al., 1996
Brazil–Caucasian	0.373	Arruda et al., 1998
European-White	0.362	Franco et al., 1998
French	0.36	Mornet et al., 1997
British	0.36	Papapetrou et al., 1996
United Kingdom	0.353	Gudnason et al., 1998
White Americans (U.S.)	0.35	Stevenson et al., 1997
South Wales (U.K.)	0.32	Clark et al., 1998
Middle Europe	0.312	Gudnason et al., 1998
German	0.31	Koch et al., 1998
lrish	0.27	Whitehead et al., 1995
Utah Mormons (U.S.)	0.27	Papapetrou et al., 1996
Japanese	0.27	Papapetrou et al., 1996
Dutch	0.26	van de Put et al., 1996
Amerindian	0.24	Franco et al., 1998
Baltic	0.233	Gudnason et al., 1998
U.S. Population II	0.22	Ou et al., 1996
U.S. Population I	0.21	Ou et al., 1996
Brazil Black	0.2	Arruda et al., 1998
Brazilian–Black	0.12	Franco et al., 1998
Brazil Indian	0.114	Arruda et al., 1998
African–Americans (U.S.)	0.11	Stevenson et al., 1997
African Black	0.052	Franco et al., 1998
	Present study	
Ashkenazi Population	0.477	
Texas Population	0.287	

The two most common forms of the mutation are: C677T, and A1298C. As a result of the genetic mutation there is no MTHFR, an enzyme, to convert folic acid to the metabolizable methylfolate, an essential component of the cell's methylation cycle. An associated high level of homocysteine is a consequence of the MTHFR gene mutation (Rozen, 1997, 2002; and Spotila et al., 2003).

Diagram 1 CELL METHYLATION CYCLE



Fig. 1. Simplified scheme of DNA methylation/synthesis cycle. Dihydrofolate (DHF), tetrahydrofolate (THF), methionine (MET), enosvlhomocysteine (SAH), homocysteine (Hcy), 5,10-methylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) methionine synthase(MS), methionine synthase reductase (MSR), betaine:homocysteine methyltransferase (BHMT), cystathionine-synthase (CBS), B6 vitamin (B6), and B12 vitamins (B12).

OVERVIEW

In particular, one of the sequela of MTHFR is hypotonia. Vision related manifestations of hypotonia include binocular eccentric fixation, eye movements disorders, convergence and accommodation insufficiencies, latent hyperopia, suppression, and poor binocular vision (Al-Essa, et al., 1999; Berman, 2013; Black, 2008; Bodenstgeiner, 1994; Boustany et al, 1983, Brooke, Carroll and Ringel, 1979; Cohen et al., 1973; Fattal-Valevski, et al. 2000; and Kondo, Nagataki, and Miyagi, 1990). While optometrists are familiar with treating the vision disorders, they may not be familiar with the underlying MTHFR.

Two queries made to:http://www.ncbi.nlm.nih.gov/sites/gquery were for MTHFR and VISION, which showed 155 articles, and HOMOCYSTEINE and VISION, which showed 582 articles. Another two queries to the database were: MTHFR and OPTOMETRY, and HOMOCYSTEINE and OPTOMETRY, which revealed zero, and two articles respectively.

In regard to hypotonia, the query HYPOTONIA AND VISION found 77 articles and HYPOTONIA AND MTHFR showed four publications.

The most frequent articles were on the following topics: (1) MTHFR: Behcet's disease, primary open angle glaucoma, primary closed angle, glaucoma, age related macular degeneration, and Leber Hereditary Optic Neuropathy, and (2) HOMOCYSTEINE: glaucoma, central retinal vein occlusion, macular degeneration, death of retinal ganglion cells, migraine, proliferative diabetic retinopathy, rhegmatogenous retinal detachment, and non-arteritic ischaemic optic neuropathy.

Many common ocular defects are related to the MTHFR gene defect, and high homocysteine. In the diagnosis and treatment of the diseases that have been listed as a result of the literature search, it is most important that the presence or absence of either the gene defect and/or homocysteine determined. Both can be measured with blood tests.

After reading the above description of the relationship of hypotonia to vision problems, the signs and symptoms are very similiar as those described by Streff's non-malingering syndrome.

Before vision training commences, it is therefore recommended to have patients with hypotonia also tested for MTHFR and homocysteine. If the homocysteine is high, i.e. above 12, the following regime is suggested: methylfolate, B12, B2, B6, and betaine HCl. The dosages can be coordinated with the patient's care provider. It is important to note here that gluten interferers with folate absorption. Accordingly, patients found having MTHFR are put on gluten-free diets.

In addition to hypotonia, MTHFR and homocysteine are also related to primary open angle glaucoma, primary closed angle glaucoma, age-elated macular degeneration, central retinal vein occlusion, death of retinal ganglion cells, migraine, proliferative diabetic neuropathy, retinal detachment, and non-arteritic ischaemic optic neuropathy.

Email: tracht@accommotrac.com



MATHER, HYPOTONIA & VISION

Only two articles in the optometric literature discuss the ocular effects from the MTHFR gene mutation. The purpose of this presentation is to introduce these topics to those in optometric community unaware of MTHFR, its related ocular effects, and treatment.

METHODS

RESULTS

CONCLUSION

HYPOTONIA

SUPINE: RIGHT, LEFT, CENTER

TNR

FACES

DANGLING RING

LIGHTS: BLINKING CO

MOBILE

DANGLE BELL

SEATED AT TALBLE / FLOOR: F

HAND: Prehensory i

BOTTLE

LARGE OBJECTS: Va

SMALL OBJECTS

DANGLE RING

DANGLE BELL

SPOON

FACES

MIRROR

BALL

BUILDING BLOCKS

LARGE OBJECT PUZZ

HOLDING SPOON

HOLDING CRAYON, I



ISBN 0-943599-92-X

HYPOTONIA EVALUATION & TREATMENT

Table 2 **HYPOTONIA TRAINING**

TRAINING	PAGE
	31, 32
	14, 49
LORS	
GHT LEFT CENTER	
egration	35, 66
	75
v texture, shape, color	
	59, 62, 66
	11
	31
	63
	70
	72
	77, 80
LES	77
ENCIL	86

Gesell, Arnold, Ilg, Frances L andBullis, Glenna E (1998) SOURCE VISION: IT'S DEVELOPMENT IN INFANT AND CHILD Santa Ana, CA: Optometric Extension Program Foundation

Table 3 **SIGNS & SYMPTOMS**

SIGNS & SYMPTOMS

CLINICAL OBSERVATIONS: CHILDREN WITH HYPOTONIA

POOR EYE MOVEMENTS	Typically the head leads the eyes in following objects and in tracking	
POOR EYE FOCUSING	Cannot sustain reading or other near vision tasks	
REFRACTIVE STATES	Children are usually farsighted	
BINOCULAR VISION	The child may see double and /or have an eye that turns in or out	
EYE - HAND COORDINATION	Usually slow in developing due to the lack of accu- rate eye movements and eye focusing	
SKILLS: With the lack of these vision skills, the child will typically use other senses to obtain information about his space world, i.e. touch.		

Diagram 2 **VISION - MOTOR MODEL**



Vision Improvement Center of Seattle, PS 108 5th Avenue South Suite C-1 Seattle, WA 98104

REFERENCES

Al-Essa MA, Al Amir A, Rashed M, Al Jishi E, Abutaleb A, Mobaireek K, Shin YS, Ozand PT. Clinical, fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomography of the brain, MR spectrocopy, and therapeutic attempts in methylenetetrahydrofolate reductase deficiency. Brain Dev 1999; 21(5): 345-9

Berman JL. Poor vision, deafness, hypotonia...with pupillary membranes. J Pediatr Ophthalmol Strabismus 2013; 50(10): 9-26

Black MM. Effects of vitamin B12 and folate deficiency on brain development in children. Food Nutr bull 2008; 29(2): S126-31

Bodensteiner JB. Congenital myopathies. Muscle & Nerve 1994; 17: 131-44

Boustany RN, Aprille JR. Halperin J, Levy H, DeLong GR. Mitochondrial cytochrome deficiency presenting as a myopathy with hypotonia, external ophthalmoplegia, and lactic acidosis in an infant and as fatal hepatopathy in a second cousin. Ann Neurol 1983; 14: 462-70

Brooke MH, Carroll JE, Ringel SP. Congenital hypotonia revisited. Muscle & Nerve 1979; 2: 84-100

Cohen MM, Hall BD, Smith DW, Graham CB, Lampert KJ. A new syndrome with hypotonia, obesity, mental deficiency, and facial, oral, ocular, and limb anomalies. The Journal of Pediatrics 1973; 83(2): 280-4

Fattal-Valevski a, Bassan H, Korman SH, Lerman-Sagie T, Gutman A, Harel S. Methylenetetrahydrofolate reductase deficiency: importance of early diagnosis. J child Neurol 2000; 15(8): 539-43

Gesell A, Ilg FL. Child development. Harper & Brothers: New York, 1949 Gesell A, Ilg FL, Bullis GE. Vision: Its development in infant and child. Harper & Brothers: New York. 1950

Kondo I, Nagataki S, Miyagi N. The Cohen syndrome: Does mottled retina separate a Finnish and a Jewish type? American Journal of Medical Genetics 1990; 37: 109-13

Rady PL, Tyring, SK, Hudnall SD, Vargas T, Kellner LH, Nitowsky H, Matalon, RK. Methylenetetrahydrofolate reductase (MTHFR): The incidence of mutations C677T and A1298C in the Ashkenazi Jewish population. American Journal of Genetics 1999; 86: 380-4

Rozen R. Genetic predisposition to hyperhomocysteinemia: Deficiency of methylenetetrahydrofolate reductase (MTHFR). Thrombosis and Haemostasis 1997; 78(1): 523-6

Rozen R. Methylenetetrahydrofolate reductase: a link between folate and riboflavin? Am J Clin Nutr. 2002 Aug;76(2):301-2

Spotila LD, Jacques PF, Berger PB, Ballman KV, Ellison RC, Rozen R. Age dependence of the influence of methylenetetrahydrofolate reductase genotype on plasma homocysteine level. Am J Epidemiol. 2003 Nov 1;158(9):871-7.

Streff, J.W., A Non-Malingering Syndrome. Eastern Seaboard Visual Training Conference, Washington D.C., 1961.

Streff JW. Preliminary observations on a non-malingering syndrome. Optom Wkly 57 (1961): 33-4.

Streff JW. Preliminary observations on a non-malingering syndrome. Opt Weekly 1962 Mar; 53(12): 536-537

Streff, J. Fixation and Eye Tracking Losses Associated with Streff Syndrome. Optometric Vision Development 1994;25(2): 70-78

Streff, J. Juvenile Bilateral Functional Amblyopia: The Streff Syndrome. In Behavioral Aspects of Vision Care (Vol 42, No. 1, pp. 1-28). Santa Ana, CA: Optometric Extension Program, 2001